Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026PLoS ONEOpen Access

Long-term ACE inhibitor use linked to ~15% lower overall cancer risk vs ARBs.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does exclusive treatment with ACEIs reduce the risk of cancer compared to ARBs in hypertensive adults?

Population

423,423 hypertensive adults aged 40 years or older who were free of cancer at baseline

Comparison

Exclusive treatment with Angiotensin-converting… vs Exclusive treatment with Angiotensin receptor…

Design

Cohort

Follow-up

from 2002 through 2024

Key result

Exclusive long-term treatment with ACE inhibitors was associated with lower overall odds of developing cancer compared to ARB therapy (OR 0.851), although associations varied across specific cancer types.

Authors

BBBelle Tamir BrahmsSAShani AfekMHMichael Hopp

Discussion

Loading...

Member takes

Overview

Should not yet influence antihypertensive choice; leaves open differential cancer associations requiring prospective validation.

Key Points

  • To compare cancer incidence among patients treated exclusively with ACEIs versus ARBs.
  • Retrospective cohort study using electronic health records from Clalit Health Services.
  • Included hypertensive adults aged 40 and older, free of cancer on January 1, 2000.
  • Final cohort consisted of 346,405 ACEI users and 77,018 ARB users, with follow-up from 2002 to 2024.
  • ACEI therapy was associated with lower overall odds of cancer compared to ARB therapy.
  • Variations in cancer types observed; lower odds for several malignancies among ACEI users.
  • Differences in age at diagnosis and time to diagnosis noted between treatment groups.

Study Design

Type

Cohort (n=423,423)

Structured PICO

Does exclusive treatment with ACEIs reduce the risk of cancer compared to ARBs in hypertensive adults?

P
Population
423,423 hypertensive adults aged 40 years or older, free of cancer at baseline, treated exclusively with ACEIs or ARBs and followed for up to 23 years.
E
Exposure
Exclusive treatment with Angiotensin-converting enzyme inhibitors (ACEIs)
C
Comparator
Exclusive treatment with Angiotensin receptor blockers (ARBs)
O
Outcome
Diagnosis of any cancersafety

Main Result

Odds Ratio: 0.851 (95% CI 0.838–0.865)

Absolute Event Rate: 56.5% vs 61.6%

p-value: p=<0.001

In a large retrospective cohort, long-term exclusive use of ACE inhibitors was associated with a lower risk of cancer compared to ARBs, contributing to the safety profile evaluation of RAAS-modulating therapies.

Limitations

  • Observational retrospective cohort design cannot establish causality.
  • Residual confounding remains possible despite adjustment for demographic and exposure-related factors.
  • Treatment allocation was not random, and prescribing patterns may have differed according to unmeasured clinical characteristics.
  • Study population was derived from a single national healthcare organization and may not be fully representative of other healthcare systems.
  • Potential influence of unmeasured clinical and behavioral factors cannot be completely excluded.
  • Observational design precludes causal inference

Cite This Study

Brahms et al. (2026) conducted a cohort in Hypertension (n=423,423). Angiotensin-converting enzyme inhibitors (ACEIs) vs. Angiotensin receptor blockers (ARBs) was evaluated on Diagnosis of any cancer (OR 0.851, 95% CI 0.838-0.865, p=<0.001). Exclusive long-term treatment with ACE inhibitors was associated with lower overall odds of developing cancer compared to ARB therapy (OR 0.851), although associations varied across specific cancer types.

synapsesocial.com/papers/6a65a468d3aea3239cd770bahttps://doi.org/10.1371/journal.pone.0354248
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Association Between Angiotensin Receptor Blocker Use and Cardiovascular Outcomes Compared With Angiotensin-Converting Enzyme Inhibitors in Patients With Atherosclerotic Cardiovascular Disease: A Real-World Cohort Study2026
  2. 2Comparative effectiveness of antihypertensive drug classes in patients with gastrointestinal malignancy and incident hypertension.2026
  3. 3Comparative cardiovascular outcomes of renin–angiotensin system inhibitors in patients receiving maintenance hemodialysis: a large real-world cohort study2026 · 1 citations
  4. 4Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers: Multidatabase Target Trial Emulation Studies2025 · 10 citations
  5. 5Angiotensin receptor blocker and angiotensin-converting enzyme inhibitor use and survival in gastric cancer patients: a Finnish nationwide cohort study2025